S&P 500   4,410.13
DOW   34,364.50
QQQ   353.30
S&P 500   4,410.13
DOW   34,364.50
QQQ   353.30
S&P 500   4,410.13
DOW   34,364.50
QQQ   353.30
S&P 500   4,410.13
DOW   34,364.50
QQQ   353.30
NASDAQ:CDXS

Codexis Stock Forecast, Price & News

$20.54
+0.71 (+3.58%)
(As of 01/24/2022 12:00 AM ET)
Add
Compare
Today's Range
$18.41
$20.68
50-Day Range
$19.83
$38.27
52-Week Range
$16.55
$42.01
Volume
921,077 shs
Average Volume
631,534 shs
Market Capitalization
$1.33 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.55
30 days | 90 days | 365 days | Advanced Chart
Receive CDXS News and Ratings via Email

Sign-up to receive the latest news and ratings for Codexis and its competitors with MarketBeat's FREE daily newsletter.


Codexis logo

About Codexis

Codexis, Inc. is an enzyme engineering company, which engages in the development and sale of therapeutics. It operates through the Performance Enzymes and Novel Biotherapeutics segments. The Performance Enzymes segment commercializes CodeEvolver protein engineering technology platform and products in the pharmaceuticals market. The Novel Biotherapeutics segment targets new opportunities to discover and improve biotherapeutic drug candidates. Its products include screening kits and Codex HiFi Hot Start DNA Polymerase. The company was founded in January 2002 and is headquartered in Redwood City, CA.

Headlines

What Makes Codexis (CDXS) a New Strong Buy Stock
January 11, 2022 |  finance.yahoo.com
Codexis (NASDAQ:CDXS) Shares Gap Down to $26.75
January 7, 2022 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Industry
Industrial organic chemicals
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:CDXS
CUSIP
19200510
Employees
181
Year Founded
N/A

Sales & Book Value

Annual Sales
$69.06 million
Book Value
$2.87 per share

Profitability

Net Income
$-24.01 million
Pretax Margin
-14.69%

Debt

Price-To-Earnings

Miscellaneous

Free Float
60,009,000
Market Cap
$1.33 billion
Optionable
Optionable

Company Calendar

Last Earnings
11/04/2021
Today
1/25/2022
Next Earnings (Estimated)
2/24/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.08 out of 5 stars

Medical Sector

542nd out of 1,415 stocks

Industrial Organic Chemicals Industry

14th out of 23 stocks

Analyst Opinion: 3.5Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.0 5 -4 -3 -2 -1 -












Codexis (NASDAQ:CDXS) Frequently Asked Questions

Is Codexis a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Codexis in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Codexis stock.
View analyst ratings for Codexis
or view top-rated stocks.

How has Codexis' stock been impacted by COVID-19?

Codexis' stock was trading at $10.12 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, CDXS shares have increased by 103.0% and is now trading at $20.54.
View which stocks have been most impacted by COVID-19
.

When is Codexis' next earnings date?

Codexis is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for Codexis
.

How were Codexis' earnings last quarter?

Codexis, Inc. (NASDAQ:CDXS) announced its earnings results on Thursday, November, 4th. The biotechnology company reported $0.03 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.09) by $0.12. The biotechnology company had revenue of $36.77 million for the quarter, compared to analyst estimates of $28.52 million. Codexis had a negative trailing twelve-month return on equity of 9.02% and a negative net margin of 14.82%. The business's quarterly revenue was up 100.0% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.10) EPS.
View Codexis' earnings history
.

What guidance has Codexis issued on next quarter's earnings?

Codexis updated its FY 2021 earnings guidance on Thursday, December, 2nd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $98 million-$103 million, compared to the consensus revenue estimate of $101.77 million.

What price target have analysts set for CDXS?

5 analysts have issued twelve-month price objectives for Codexis' stock. Their forecasts range from $30.00 to $38.00. On average, they anticipate Codexis' share price to reach $32.80 in the next twelve months. This suggests a possible upside of 59.7% from the stock's current price.
View analysts' price targets for Codexis
or view top-rated stocks among Wall Street analysts.

Who are Codexis' key executives?

Codexis' management team includes the following people:
  • John J. Nicols, President, Chief Executive Officer & Director (LinkedIn Profile)
  • Karl A. Schoene, Senior Vice President-Development & Operations
  • Ross Taylor, Chief Financial Officer & Senior Vice President
  • Stefan Lutz, Senior Vice President-Research
  • Asli Aras, Vice President-Corporate Development

What is John J. Nicols' approval rating as Codexis' CEO?

25 employees have rated Codexis CEO John J. Nicols on Glassdoor.com. John J. Nicols has an approval rating of 68% among Codexis' employees.

What other stocks do shareholders of Codexis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Codexis investors own include Advanced Micro Devices (AMD), Sorrento Therapeutics (SRNE), AbbVie (ABBV), Micron Technology (MU), (CGC), Enphase Energy (ENPH), Intellia Therapeutics (NTLA), NVIDIA (NVDA), OPKO Health (OPK) and Antares Pharma (ATRS).

What is Codexis' stock symbol?

Codexis trades on the NASDAQ under the ticker symbol "CDXS."

Who are Codexis' major shareholders?

Codexis' stock is owned by a number of retail and institutional investors. Top institutional investors include Baillie Gifford & Co. (11.07%), Taylor Frigon Capital Management LLC (0.31%), Russell Investments Group Ltd. (0.15%), Conestoga Capital Advisors LLC (0.11%), Exchange Traded Concepts LLC (0.10%) and Pendal Group Ltd (0.05%). Company insiders that own Codexis stock include Bernard J Kelley, Byron L Dorgan, Dennis P Wolf, John J Nicols, Patrick Y Yang and Thomas R Baruch.
View institutional ownership trends for Codexis
.

Which institutional investors are selling Codexis stock?

CDXS stock was sold by a variety of institutional investors in the last quarter, including Exchange Traded Concepts LLC, Taylor Frigon Capital Management LLC, Strs Ohio, and Conestoga Capital Advisors LLC. Company insiders that have sold Codexis company stock in the last year include Bernard J Kelley, Byron L Dorgan, Dennis P Wolf, John J Nicols, and Patrick Y Yang.
View insider buying and selling activity for Codexis
or view top insider-selling stocks.

Which institutional investors are buying Codexis stock?

CDXS stock was bought by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., Russell Investments Group Ltd., and Pendal Group Ltd.
View insider buying and selling activity for Codexis
or or view top insider-buying stocks.

How do I buy shares of Codexis?

Shares of CDXS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Codexis' stock price today?

One share of CDXS stock can currently be purchased for approximately $20.54.

How much money does Codexis make?

Codexis has a market capitalization of $1.33 billion and generates $69.06 million in revenue each year. The biotechnology company earns $-24.01 million in net income (profit) each year or ($0.24) on an earnings per share basis.

How many employees does Codexis have?

Codexis employs 181 workers across the globe.

What is Codexis' official website?

The official website for Codexis is www.codexis.com.

Where are Codexis' headquarters?

Codexis is headquartered at 200 PENOBSCOT DRIVE, REDWOOD CITY CA, 94063.

How can I contact Codexis?

Codexis' mailing address is 200 PENOBSCOT DRIVE, REDWOOD CITY CA, 94063. The biotechnology company can be reached via phone at (650) 421-8100, via email at [email protected], or via fax at 650-421-8102.


This page was last updated on 1/25/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.